Katina Dorton currently serves on the board of directors of Mallinckrodt Pharmaceutics, T Scan Therapeutics, Fulcrum Therapeutics, and Sonoma Biotherapeutics. She has held numerous board leadership positions, including lead independent director, governance committee chair, audit committee chair, and compensation committee chair. Dorton has held CFO positions at several biotechnology companies, including Nodthera Inc., Repare Therapeutics, AVROBIO, and Immatics GmbH. Previously, Dorton served as a managing director in investment banking for Morgan Stanley for more than 15 years, where she had responsibility for running global businesses. She also practiced law as an M&A and securities attorney at Sullivan & Cromwell. Dorton is on the board of the NACD Research Triangle Chapter. She is NACD Directorship Certified® and an NACD Governance Fellow. She was named to the NACD Directorship 100™ in 2020 and was named as one of Women Inc.’s 2019 Most Influential Corporate Directors.